In fact, only non-selective SGLT2 inhibitors reduced the risk of fatal and nonfatal stroke (HR, 0.78; 95% CI, 0.64–0.94) as compared with placebo, whereas those with high selectivity did not (HR, 1.06; 95% CI, 0.92–1.22) (Fig. 3B), with a significant interaction between the two pharmacological groups (p = 0.018). The gene discussed is SLC5A2; the disease is stroke disorder.